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Abstract
In the last decade, significant advances have been made in the treatment of patients with 
Myelodysplastic  Syndromes  (MDS).    Although  best  supportive  care  continues  to  have  an
important role in the management of MDS, to
according to the IPSS risk group, karyotype, patient’s age, comorbidities, and compliance. 
Hematopoietic growth factors play a major role in lower risk MDS patients,
dose  erithropoiesis  stimulating  agents  and  thrombopoietic  receptor  agonists.  Standard 
supportive care should also include iron chelating therapy to reduce organ damage related to 
iron overload in transfusion-dependent patients. Biologic t
MDS, as lenalidomide, which has been shown to induce transfusion independence in most 
lower risk MDS patients with del5q.  Hypomethylating agents have shown efficacy in INT
2/high  risk  MDS  patients,  reducing  the  risk  of  leu
survival.  Other  agents  under  development  for  the  treatment  of  MDS  include  histone 
deacetylase inhibitors, farnesyltransferase inhibitors, clofarabine and ezatiostat.
Introducion: Myelodysplastic  Syndromes  (MDS) 
are  a  heterogeneous  group  of  clonal  disorder  of 
hematopoiesis  characterized  by  ineffective 
hematopoiesis,  morphological  signs  of  dysplasia, 
peripheral cytopenia and increased risk of develop 
Acute Myeloid Leukemia (AML). MDS
disorder of the elderly and most patients are over 70 
years  of  age  at  diagnosis.  Up  to  recently,  MDS 
treatment  was  mainly  supportive,  including 
transfusion  of  blood  components  and  antibiotics, 
while  a  minority  of  younger  patients,  with  good 
performance  status  and  without  significant 
ystem 
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In the last decade,  significant advances have been made in the treatment of patients with 
Myelodysplastic  Syndromes  (MDS).    Although  best  supportive  care  continues  to  have  an
important role in the management of MDS, to date the therapeutic approach is diversified 
according to the IPSS risk group, karyotype, patient’s age, comorbidities, and compliance. 
Hematopoietic growth factors play a major role in lower risk MDS patients, and include high 
dose  erithropoiesis  stimulating  agents  and  thrombopoietic  receptor  agonists.  Standard 
supportive care should also include iron chelating therapy to reduce organ damage related to 
dependent patients. Biologic therapies have been introduced in 
MDS, as lenalidomide, which has been shown to induce transfusion independence in most 
lower risk MDS patients with del5q.  Hypomethylating agents have shown efficacy in INT
2/high  risk  MDS  patients,  reducing  the  risk  of  leukemic  transformation  and  increasing 
survival.  Other  agents  under  development  for  the  treatment  of  MDS  include  histone 
deacetylase inhibitors, farnesyltransferase inhibitors, clofarabine and ezatiostat.
Myelodysplastic  Syndromes  (MDS) 
are  a  heterogeneous  group  of  clonal  disorder  of 
hematopoiesis  characterized  by  ineffective 
hematopoiesis,  morphological  signs  of  dysplasia, 
peripheral cytopenia and increased risk of develop 
Acute Myeloid Leukemia (AML). MDS is a typical 
disorder of the elderly and most patients are over 70 
years  of  age  at  diagnosis.  Up  to  recently,  MDS 
treatment  was  mainly  supportive,  including 
transfusion  of  blood  components  and  antibiotics, 
while  a  minority  of  younger  patients,  with  good 
erformance  status  and  without  significant 
comorbidities,  was  eligible  for  more  intensive 
treatment  including  chemotherapy  and  allogenic 
stem  cell  transplantation,  but  results  were  often 
dismal.  In the last decade, the treatment of MDS 
has  significantly  improved  by  the  introduction  of 
new agents and by different use of old drugs, so that 
the pharmacological armamentarium, as well as the 
number of MDS patients suitable for treatment are 
definitely  wider  than  in  the  past.  This  has  been 
made possible by new insights in the biology and 
pathogenesis of MDS, although many aspects of the 
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In the last  decade, significant advances have been made in the treatment of patients with 
Myelodysplastic  Syndromes  (MDS).    Although  best  supportive  care  continues  to  have  an
date the therapeutic approach is diversified 
according to the IPSS risk group, karyotype, patient’s age, comorbidities, and compliance. 
and include high 
dose  erithropoiesis  stimulating  agents  and  thrombopoietic  receptor  agonists.  Standard 
supportive care should also include iron chelating therapy to reduce organ damage related to 
herapies have been introduced in 
MDS, as lenalidomide, which has been shown to induce transfusion independence in most 
lower risk MDS patients with del5q.  Hypomethylating agents have shown efficacy in INT-
kemic  transformation  and  increasing 
survival.  Other  agents  under  development  for  the  treatment  of  MDS  include  histone 
deacetylase inhibitors, farnesyltransferase inhibitors, clofarabine and ezatiostat.
comorbidities,  was  eligible  for  more  intensive 
treatment  including  chemotherapy  and  allogenic 
stem  cell  transplantation,  but  results  were  often 
dismal.  In the last decade, the treatment of MDS 
proved  by  the  introduction  of 
new agents and by different use of old drugs, so that 
the pharmacological armamentarium, as well as the 
number of MDS patients suitable for treatment are 
definitely  wider  than  in  the  past.  This  has  been 
sights in the biology and 
pathogenesis of MDS, although many aspects of the Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
efficacy  of  the  new  drugs  are  still  unknown  and 
under investigation.
1
Considering  the  heterogeneity  of  nosographic 
entities  representing  MDS,  risk  stratification  is 
essential to target the treatment according to the risk 
of  AML  evolution  and  blood  transfusion 
requirement. In the last decade, the risk evaluation 
score  IPSS  has  guided  physicians  on  therapeutic 
decisions,  stratifying  MDS  patients  into  Low, 
Intermediate-1 (INT-1), Intermediate-2 (INT-2) and 
High risk, according to number of peripheral blood 
cytopenias,  bone  marrow  blast  percentage  and 
karyotype.
2 More recently, the WHO classification-
based  prognostic  scoring  system  (WPSS)  has 
included the WHO morphologic classification and 
underlined  the  importance  of  transfusion 
requirements  as  prognostic  factor  for  survival  in 
MDS patients.
3
Besides  disease-related  factors,  therapeutic 
decisions  in  MDS  patients  should  also  take  into 
account  other  patients’  related  factors,  as  age, 
performance  status,  comorbidities  and  quality  of 
life.  Patients’  compliance  to  the  treatment  is 
definitively  pivotal  to  achieve  therapeutic  results. 
According to the IPSS, current guidelines have been 
developed for MDS treatment.
4,5
Erithropoiesis  stimulating  agents (ESAs):  MDS 
patients  with  low-INT1  IPSS  risk,  hemoglobin 
levels lower than 10 g/dl, and serum erythropoietin 
levels <500 mIU/ml should be treated according to 
current guidelines with high dose  ESAs, as fixed 
weekly subcutaneous doses of 60–80,000U - or -
erythropoietin or 300 g darbepoetin.
4,5
Three  retrospective  studies  suggest  a  survival 
advantage for  ESAs, possibly through their  effect 
on minimizing transfusion needs and reducing iron 
overload.  Jädersten  at  al.
6 compared  121  Nordic 
patients with MDS treated with erythropoietin plus 
granulocyte colony-stimulating factor (G-CSF) to a 
disease  and  time-matched  cohort  of  237  patients 
from  Pavia,  Italy,  who  received  no  therapy.  The 
erythroid  response  rate  in  the  treated  group  was 
39%, and the median response duration 23 months. 
Those  receiving  ESA-based  therapy  had  a 
significant survival (OS) advantage (HR=0.61, 95% 
CI:0.44-0.83,  p=0.002)  without  any  difference  in 
the  risk  of  leukemic  transformation.  The  Groupe 
Francophone  des  Myelodysplasies  compared  in  a 
matched-pair  analysis  200  ESA-treated  patients 
with 200 patients from the ESA-untreated subjects 
used  to  define  the  IPSS,  and  again  demonstrated 
improved  OS  in  the  ESA  cohort  (HR=0.43,  95% 
CI:0.25-0.72), despite no difference in rates of acute 
myeloid leukemia  (AML)  transformation.
7 The 
Cleveland  group  performed  a  pooled  analysis  of 
162  published  trials  enrolling  lower-risk  MDS 
patients over a 20-year period and compared 1587 
patients treated with ESA-based therapy with 1005 
patients  treated  with  non-growth  factor  (NGF) 
approaches.
8 Growth factors (GF) produced higher 
overall response rates (39.5% vs. 31.4% for NGF, 
p=0.019),  while  NGF  yielded  better  CR/PR  rates 
(25.6%  vs.  9.1%  for  GF,  p=0.03).  Over  2  years 
follow-up,  patients  receiving  ESA-based  therapy 
demonstrated  longer  overall  and  progression-free 
survival. 
Moreover, among transfusion-dependent  MDS 
patients, a significant survival advantage has been 
demonstrated    in  patients  responding  to  ESAs  as 
compared  to  those  resistant  or  to  subjects  never 
treated with EPO (median 52 months vs. 31 months, 
p<0.0095).
9
A  meta-analysis  of  30  studies  from  1990  to 
2006  evaluating  a  total  of  1314  MDS  patients 
treated with epoetin alfa (22 studies, 925 patients) 
or darbepoetin alfa (8 studies, 389 patients) found 
no  significant  difference  in  the  pooled  erythroid 
response rates between the two agents (57.6% and 
59.4%,  respectively,  p=0.828).
10 Similarly,  no 
differences in  erythroid response rates was found 
between EPO as a single agent or combined with G-
CSF or granulocyte-macrophage-colony-stimulating 
factor  (GM-CSF).
11 Furthermore,  EPO 
monotherapy at higher doses of 60000 to 80000 U
weekly  produced  significantly  higher  erythroid 
response rates (64.5%) compared with the standard 
dose of 30000 to 40000 U weekly either as a single 
agent  (49%;  p<0.001) or  in  combination  with  G-
CSF/GM-CSF (50.6% p=0.007).
11
The combination of ESAs and G-CSF should be 
considered only in less heavily transfused patients 
(less than 2U per month), with serum erythropoietin 
levels  <500  mIU/ml,  unresponsive  to  ESAs 
alone.
4,5,12
Finally, G-CSF is  useful in neutropenic MDS 
patients  with  recurrent  or  resistant  infections  but 
should  not  be  used  for  routine  infection 
prophylaxis.
13
Thrombopoietin  receptor  agonist: 
Thrombocytopenia  occurs  at  the  time  of  initial 
diagnosis in 30% of MDS patients and represents an 
independent  adverse  prognostic  factor  for 
survival.
14,15 Platelet function may be abnormal in 
MDS, making the presence of moderate to severe 
thrombocytopenia  of  greater  concern.  Platelet 
transfusions are the only current treatment option, 
but new approaches are under investigation. Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
Romiplostim is a peptibody, increasing platelet 
production  through  the  thrombopoietin  (TPO) 
receptor  (c-Mpl).  Clinical  studies  showed  that 
romiplostim  (Nplate®,  Amgen)  increases  platelet 
counts  in healthy individuals and in  patients  with 
chronic  immune  thrombocytopenia.  In  a  recent 
phase  I/II,  multicenter,  open-label,  sequential-
cohort,  dose-escalation  study,  romiplostin  at  the 
weekly  doses  of  300,  700,  1000,  or  1500  g 
increased platelet counts in 44 MDS patients with 
low  or  INT-1 IPSS  and  mean  baseline  platelet 
counts < 50 x 10
9/L, treated with supportive care. 
Durable  platelet  response  according  to  the 
International  Working  Group  2000  criteria,  was 
achieved in 19 patients (46%) with reduction of the 
incidence  of  bleeding  events  and  platelet 
transfusions.  Treatment-related  serious  adverse 
events were reported in five patients (11%), all of 
whom in the 1500 g dose cohort, including two 
AML progressions.
16 Further studies need to clarify 
the  role  of  thrombopoietin  receptor  agonist  in 
management of thrombocytopenic MDS patients.
Lenalidomide:  Lenalidomide  is  a  4-amino-
glutarimide,  analogue  of  the  older 
immunomodulatory  drug  thalidomide.  Supposed 
mechanism  of  action  involves  modulation  of 
cellular  response  to  receptor/ligand  activation 
signals,  via  suppression  of  pro-inflammatory  and 
pro-apoptotic  cytokine  generation,  prevention  of 
angiogenesis, altered cell adhesion to bone marrow 
stroma,  and  direct  cytotoxicity  against  dysplastic 
clones.
1
Four phase II trials investigated the efficacy of 
lenalidomide  as  single  agent  in  more  than  400 
patients, with low/INT-1 MDS,  with  symptomatic 
or  transfusion-dependent  anemia,  refractory  to 
ESAs.  Patients  with  5q  deletion  are  peculiarly 
responsive to lenalidomide. Best dose and schedule 
are 10  mg/day  for  21  days  every  4  weeks.  Dose 
reduction was required in patients with renal failure 
and  altered  drug  metabolism,  especially  because 
responding  patients  may  experience  severe  dose-
related  neutropenia  and  thrombocytopenia  due  to 
selective elimination of the 5q- positive clone.
4
In the phase II registration study including 148 
patients  with  the  5q- deletion,  lenalidomide  was 
administered at a dose of 10 mg/day for a 28-day 
cycle or 10 mg/day for 21 days of a 28-day cycle.
17
Erythroid  response  occurred  in  76%  patients, 
including 67% transfusion independence and 45%  
complete  cytogenetic  responses.  The  response  to 
lenalidomide was rapid (median time to response, 
4.6 weeks; range, 1 to 49) and sustained; the median 
duration of transfusion independence had not been 
reached after a median follow-up of 104 weeks. The 
maximum  hemoglobin  concentration  reached  a 
median of 13.4 g per deciliter (range, 9.2 to 18.6), 
with  a  corresponding  median  rise  of  5.4  g  per 
deciliter  (range,  1.1  to  11.4).  Similar  data  were 
reported  by  the  results  of  French  compassionate 
program (ATU) of lenalidomide in low/INT-1 risk 
MDS with del 5q, where 62/95 pts (65%) achieved 
erythroid response, including 60 (63%) transfusion 
independence (TI).
18
In  a  double-blind  randomized  phase  III  trial 
(MDS-004), involving patients with Low-or INT-1-
Risk MDS with del5q, lenalidomide at the dose of 
10 mg/day for 21 days of each 28-day cycle was 
associated  with  better  RBC-transfusion 
independence  and  cytogenetic  responses  than  the 
dose of 5 mg/day for 28 days of each 28-day cycle, 
with  a  comparable  safety  profile,  and  should  be 
considered as a starting dose.
19
Response  rates  are  lower  in  low/INT-1 MDS 
patients  without  5q  deletion.  In  a  phase  II  study 
involving  214  transfusion-dependent  low/INT-1
MDS  non-5q  deleted  patients,  lenalidomide 
administered at 10 mg daily or 10 mg on days 1 to 
21 of a 28-day cycle induced 43% overall response 
rate  (ORR),  including  26%  transfusion 
independence and 17% reduction of more than 50% 
transfusion requirements.
20
Response to lenalidomide have been described 
also in INT-2/high-risk MDS with 5q deletion. In a 
phase II trial, of 47 patients with higher-risk MDS 
who  received  lenalidomide  10  mg/day,  13  (27%) 
achieved hematologic response including 12 RBC-
transfusion  independence.  Six  of  9  patients  with 
isolated del 5q achieved complete remission, versus 
1 of 11 and none of 27 patients with one or more 
than  one  additional  abnormality,  respectively 
(p<0.001).
21
The  karyotype-selective  therapeutic  effect  of 
lenalidomide  toward  MDS  clone  carrying  del5q 
abnormality  has  been  related  to  its inhibitory 
activity  on  two  phosphatases,  Cdc25C  and 
PP2Acalpha,  which  are  codified  by  the  common 
deleted region (CDR) and work as coregulators of 
the G(2)-M checkpoint. Treatment of del(5q) AML 
cells  with  lenalidomide  induced  G(2)  arrest  and 
apoptosis,  whereas  there  was  no  effect  in 
nondel(5q) AML cells.
22
Other  major  effects  have  been  reported  on 
RPS14, SPARC and other genes, including p53.
Sporadic  MDS  patients  treated  with 
lenalidomide progressed to AML. Although the rate 
of  AML progression does not significantly differ 
from  patients  with  similar  characteristics,  strict 
cytogenetic monitoring and the use of lenalidomide Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
within controlled therapeutic programs (registries or 
clinical trials) are required.
4
Iron-chelation therapy: Most patients with MDS 
receive  RBC  transfusions  for  symptomatic 
management of their anemia during the course of 
their  disease.  Transfusion  requirement  has  been 
identified as a major negative prognostic factor in 
MDS  patients  and  is  associated  with  shorter 
survival and an increased risk for progression into 
AML.
3 Moreover,  chronic  transfusion dependence  
leads to iron overload, which represents a serious 
treatment-related  complication,  causing  clinical 
consequences as cirrhosis, dilated cardiomyopathy, 
and  progressive  dysfunction  of  the  endocrine 
glands.
23,24 This  is  of  greatest  concern  in  patients 
with  lower-risk  MDS  whose  expected  survival  is 
measured  in  years.  Moreover,  in  patients 
undergoing myeloablative stem cell transplantation 
elevated  pre-transplantation  serum  ferritin  is 
strongly associated with lower overall and disease-
free  survival  and  increased  transplant-related 
mortality.
25
Case  control studies, prospective surveys, and 
phase II studies indicate that iron chelation therapy 
reduces iron load as measured by changes in serum 
ferritin and may prolong overall survival.
26,27
In  a  retrospective,  single-institution  analysis, 
chelation  therapy  emerged  as  the  only  significant 
factor  improving  overall  survival  in  multivariate 
analysis  in  low- or  INT-1-risk  patients.  Median 
survival  was  greater  than  160  months  in  patients 
who received chelation therapy compared with 40 
months in patients who did not (p<0.03).
26
Similarly, in the prospective survey performed 
by  the  Groupe  Français  des  Myélodysplasies 
(GFM),  in  97  low  /INT-1 regularly  transfused 
patients, the median survival was 124 months for 
patients receiving chelation  therapy  vs 53 months 
for  non  chelated  patients  (p<0.0003).  In  the 
multivariate  Cox analysis, adequate chelation  was 
the  strongest  independent  factor  associated  with 
improved OS.
27
Chelation therapy significantly decreased serum 
ferritin  levels  over  time  in  multicenter  phase  II 
clinical trials.
28,29 In a phase  II open-label, 3-year 
study, List et al.
28 evaluated safety and efficacy of 
deferasirox (Exjade®, Novartis) 20 to 40 mg/kg per 
day  in  176  RBC  transfusion-dependent,  low  and 
INT-1 patients (US-03). Mean serum ferritin level 
significantly decreased from baseline (3397 ± 233 
μg/mL) to month 12 (2501 ± 139 μ/mL). The labile 
plasma iron (LPI) concentration, a measure of the 
reactive  species  of  NTBI,  was  reduced  from  0.4 
μmol/L at baseline to non-detectable at 3 months in 
all patients, and remained within the normal range 
for the remaining follow-up. The reduction of LPI 
and  of  reactive  oxygen  species  is  one  of  the 
mechanisms  described  for  the  improvement  of 
erythropoiesis  observed  in  some  patients 
undergoing iron-chelating therapy.
The multicenter Exjade Evaluation of Patients’ 
Iron Chelation (EPIC) study recruited 1744 patients 
with  transfusional  hemosiderosis  deriving  from 
various  types  of  anemia,  including  341  MDS 
patients.  Deferasirox  was  administered,  based  on 
transfusional  iron  intake,  at  20  mg/kg/day  for 
patients  receiving  2-4  packed  red  blood  cell 
units/month,  while  10  or  30  mg/kg/day  were 
recommended for patients receiving fewer or more 
transfusions,  respectively.  Dose  adjustments  were 
based  on  3-month  serum  ferritin  trends  and 
continuous  assessment  of  safety  markers.  Median 
serum ferritin after 1 year of deferasirox treatment 
significantly decreased by a median of 264 ng/mL 
from baseline (P<0.0001).
29
Current NCCN guidelines recommend the use 
of deferasirox in the treatment of iron overload for 
low  and  INT-1-risk  MDS  patients,  anticipated  to 
receive,  or  having  received  greater  than  20  RBC 
transfusions  and/or  who  will  reach  serum  ferritin 
level >2500 μg/L.
5 The goal is to maintain ferritin < 
1000  μg/L,  thereby  preventing  accumulation  of 
NTBI and the adverse effects on cardiac, hepatic, 
and endocrine function.
Hypomethylating  agents:  Azacitidine  and 
decitabine were approved by the US Food and Drug 
Administration (FDA) for treatment of patients with 
MDS in 2004 and 2006, respectively. The European 
Medicines  Agency  (EMEA)  formally  approved 
azacitidine for MDS and AML treatment in March 
2009.  These  agents  are  now  used  for  MDS 
treatment  in  most  countries  in  the  developed 
world.
30,31
The main biologic effect of these drugs consists 
in  the  inhibition  of  DNA  methyltransferases 
followed by DNA hypomethylation and reactivation 
of the expression of epigenetically silenced tumor-
suppressor genes. Furthermore, other mechanisms, 
such as direct cytotoxicity, DNA-damage response 
and apoptosis, are induced.
30
Although hypomethylating agents have existed 
for  about  40  years,  their  efficacy  has  been 
demonstrated  in  hematologic  malignancies 
(especially MDS), just in the last 10 years (Table 
1).  The  phase  III,  randomized,  controlled  trial, 
CALGB 9221 randomized 191 MDS patients in 2 
arms,  azacitidine  75  mg/m
2 daily  given 
subcutaneously for 7 days every 28 days versus best Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
Table 1: Main trials using hypomethylating agents in MDS. Diagnosis are listed according to the F.A.B. Classification. CR also 
include marrow CR, according to modified IWG criteria (2006).
Trial Patients 
(n)
Diagnosis
(n) Treatment CR
(%)
PR
(%)
HI
(%) Ref.
CALGB 8421 48
RAEB (23)
RAEB-t (24)
AML (1)
AZA-SD i.v. 15 2 27 26
CALGB 8921 70
RA/RARS (11)
RAEB (19)
RAEB-t (16)
CMML (14)
AML (10)
AZA-SD s.c. 17 0 23 26
CALGB 9221 150*
41
RA/RARS (49)
RAEB (70)
RAEB-t (33)
CMML (20)
AML (19)
Aza-SD
BSC
9
0
3
0
33
17 24
AZA-001 phase 
III**
179
179
RAEB (207)
RAEB-t (123)
CMML (11)
AML (2)
AZA-SD
Convent. Care
17
8
12
4
49
29 27
GMDSSG/
EORTC 06011 ° 233 IPSS Int-2 (128)
IPSS high (105)
DAC °°
BSC
13
0
6
0
15
2 28
MD Anderson 64
14
17
IPSS Int-1 (19)
IPSS Int-2 (26)
IPSS High (11)
Not-appl. (39)
DAC 
20 mg/m
2 iv 5 d
20 mg/m
2 sc 5 d 10 
mg/m
2 iv 10 d
58 1 14 30
ADOPT 99
RA/RARS (37)
RAEB/RAEB-t (51)
CMML (11)
DAC
20 mg/m
2 iv 5 d 32 0 18 31
Aza-SD (standard dose): azacitidine 75 mg/m
2 daily, subcutaneously for 7 days every 28 days; BSC: best supportive care; convent. 
care: best supportive care, low-dose cytarabine, or intensive chemotherapy. DAC: Decitabine, °°15 mg/m
2 i.v. over 4 hours, every 8 
hours  for  three  days,  every  6  weeks,  for a  maximum  of  8  cycles.  *51  patients received  Aza-SD  at  disease  progression,  after 
observation. **  Overall survival and time to AML transformation were  significantly longer  for  the Aza-arm (21.5  versus 11.5 
months, p= 0.0045, and 15 versus 10.1 months, p<0.0001, respectively). ° PFS was significanlt longer in the DAC-arm (0.55 versus 
0.25 years, p=0.004), while time to AML or death were not significantly different in the two arms.
supportive  care.
32 Patients  in  the  supportive  care 
group  were  allowed  to  cross-over  to  azacitidine 
after  4  months,  in  case  of  disease  progression. 
Responses  occurred  in  60%  of  patients  on 
azacitidine (7% CR, 16% PR, 37% HI) and in 5% 
(HI)  of  those  receiving  supportive  care  (p  < 
0.0001). Median time to leukemic transformation or 
death  was  21  months  for  azacitidine  versus  12 
months  for  supportive  care  (p=0.007). 
Transformation to AML occurred as the first event 
in  15%  of  patients  on  azacitidine  and  in  38%  of 
patients  receiving  supportive  care  (p=0.001). 
Overall  quality  of  life  and  social  functioning, 
especially  fatigue  and  psychological  state,  were 
significantly improved by azacitidine.
33
Later  on,  data  on  268  patients  treated  with 
azacitidine  (75mg/m
2/day  for  7  days)  in  the 
CALGB 9221 and in 2 previous protocols (CALGB 
8421, intravenous infusion and 8921, subcutaneous) 
were  re-analyzed  according  to  the  IWG  response 
criteria, for  azacitidine marketing approval by the 
U.S.  FDA.
34 Global  response  (CR  +  PR)  to 
azacitidine  was  15.2%,  rates  were  similar  in  all 
MDS  subtypes  and  AML,  and  lasted  at  least  9 
months.  In  addition,  about  19%  of  azacitidine-
treated patients achieved hematologic improvement 
(HI)  and  two  thirds  of  transfusion-dependent 
patients  became  transfusion  independent. 
Transformation  into  AML  occurred  in  44%  of 
patients  in  the  observation  arm,  versus  14%  of 
patients randomized to azacitidine and 12% of those 
crossing-over to azacitidine after observation.
These  data  were  confirmed  by  the  AZA-001 
phase  III,  international,  multicentre,  controlled, 
parallel-group, open-label trial, in 358 patients with 
higher-risk  MDS.  Patients  were  one-to-one 
randomly assigned to receive azacitidine (75 mg/m
2  
daily for 7 days every 28 days) or conventional care 
(best  supportive  care,  low-dose  cytarabine,  or 
intensive chemotherapy).
35 After a median follow-
up  of  21.1  months,  median  overall  survival  was 
24.5 months for the azacitidine group versus 15.0 
months  for  the  conventional  care  group  (hazard 
ratio  0.58;  95%  CI  0.43-0.77;  stratified  log-rank Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
p=0.0001).  This  study  definitively  showed  that 
azacitidine  increases  overall  survival  in  patients 
with  higher-risk  myelodysplastic  syndromes, 
compared to conventional care. An oral preparation 
of azacitidine is in development.
The  alternative  hypomethylating  agent 
decitabine, was used at 15 mg/m
2 i.v. over 4 hours, 
three-times daily, for three consecutive days every 6 
weeks, in the GMDSSG/EORTC 06011 randomized 
phase III trial.  In this study, comparing low dose 
decitabine to supportive care in 233 patients over 60 
years, with primary or secondary MDS or CMML, a 
34%  ORR  (13%  CR,  6%  PR,  and  15%  HI)  was 
obtained  [36].  Probably  due  to  the  design  of  the 
study, allowing a maximum of 8 decitabine cycles, 
the decitabine dose and the absence of mainteinance 
treatment, no significant differences in survival and 
time  to  AML  were  observed.  The  D-0007  US 
registration trial using the same decitabine dose and 
schedule, showed similar response rates and a trend 
towards longer median time to AML progression or 
survival  in  patients  treated  with  decitabine 
compared  to  supportive  care  alone.
37 Higher 
responses rates were observed using decitabine i.v. 
at 20 mg/m
2 daily for 5 consecutive days every 4 
weeks in the outpatient setting, with 32% ORR and 
18% HI.
38,39
Treatment  with  hypomethylating  agents 
(azacitidine/decitabine)  was shown to be superior 
to intensive chemotherapy in terms of response rate 
and  survival  in  patients  with  AML  or  high-risk 
MDS and chromosome 5 and 7 abnormalities.
40
Current  guidelines  from  the  National 
Comprehensive  Cancer  Network  (NCCN) 
(http://www.nccn.org) recommend azacitidine for at 
least 6 cycles, for patients with high-risk MDS, with 
decitabine as alternative.
5 This recommendation is 
due  to  the  survival  advantage  observed  with 
azacitidine  in  the  AZA-001  trial.  Azacitidine and 
decitabine do not appear to be curative; continued 
therapy is necessary to maintain response.
Azacitidine was also shown to be a feasible and 
effective  treatment  for  patients  with  lower  risk 
MDS  inducing  45-60%  overall  response  rate 
according to different studies.
32,34,41,42
HDAC  inhibitors: Histones  play  an  important 
structural role in the eukaryotic nucleus. Numerous 
histone  posttranslational  modifications,  commonly 
known as the ‘‘histone code’’, result in changes in 
the accessibility of associated DNA to transcription, 
and  alter  interactions  of  the  nucleosome  with 
chromatin-associated  proteins.  Among  these 
modifications,  deacetylation  of  lysine  residues  on 
histones  has  the  potential  to  compact  chromatin 
resulting in transcriptional gene repression.
30
Histone  Deacetylase  (HDAC)  inhibitors  are  a 
class of drugs which inhibit the activity of class I, 
class  II  and  class  IV  HDACs.  After  HDAC 
inhibition  with  the  resulting  hyperacetylation  of 
lysine  residues  in  the  histone  tails,  chromatin 
structure  shifts  to  a  transcriptionally  active  state, 
with re-expression of silenced genes. Additionally, 
it is likely that part of HDAC inhibitors’ effects on 
cellular profile might be independent of chromatin 
state  modification  and  related  to  deacetylation  of 
non-histone proteins. HDAC inhibitors may modify 
stability of the protein by altering chaperone protein 
function  or  preventing  ubiquitinilation  and 
proteosome degradation and  may interfere with the 
subcellular  localization,  DNA-binding  activity, 
protein-protein  interaction  of  several  non  histone 
proteins,  such  as  transcription  factors  or  signal 
transducers, by increasing their acetylation. Finally 
HDAC  inhibitors  may  induce  growth  arrest, 
differentiation or apoptosis in vitro and in vivo.
30
Some  compounds  inhibit  specific  HDAC 
enzymes,  such  as  entinostat  (MS-275)  or 
MGCD0103  (MethylGene),  which  selectively 
inhibit only class I HDACs. Other agents, such as 
panobinostat  (LBH589),  more  broadly  inhibit 
HDACs.  In  clinical  trials,  most  HDAC  inhibitors 
have  been  associated  with  gastrointestinal  side 
effects, severe fatigue, thrombocytopenia and QTc 
prolongation as the most common treatment-related 
adverse events.
30,43
Preliminary data in MDS and AML have bee 
reported for valproic acid, sodium phenylbutyrate, 
vorinostat  (suberoylanilide  hydroxamic  acid, 
Zolinza) entinostat (SNDX-275/MS-275), belinostat 
(PXD101),  romidepsin  (FK228 / FR901229 /
depsipepide),  panobinostat  (NVP-LBH589)  and 
MGCD0103.
30,43
HDAC  inhibitors  have  shown  limited  single-
agent activity in MDS,  so that most expectations 
for  these  drugs  derive  from  combination  studies 
with hypomethylating agents or other agents with in 
vitro synergism.
The fatty acid sodium phenylbutyrate sodium as 
a continuous i.v. infusion was administered alone or 
in sequential combination with azacitidine to AML 
and  MDS  patients  in  small  phase  II  studies,  but 
because  of  the  inconvenient  schedule  required  to 
achieve biologically effective serum concentrations, 
sodium  phenylbutyrate  has  not  been  further 
developed.
30,43
Valproic acid has been used in monotherapy or 
in  combination  with  ATRA  or  hypomethylating 
agents in MDS and AML patients. As single-agent , Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
response  were  observed  in  8  out  of  18  patients, 
including 1 partial remission.
44 In combination with 
ATRA,  response  rates  were  6%  in  patients  with 
Refractory Anemia with Excess Blast (RAEB) and 
and  16%  in  AML  unfit  to  receive  intensive 
chemotherapy.
45 Hematologic  improvement  and 
stabilization of the disease was also observed. In the 
Italian  multicenter  GIMEMA  trial  MDS0205 
combining  azacitidine  at  standard  doses  with 
valproic  acid  in  INT-2/high  risk  MDS  patients, 
higher  response  rates  were  observed  in  patients 
reaching  plasma  concentration  of  50  μg/mL  of 
valproic  acid  on  day  1  of  azacitidine  treatment, 
suggesting  that  the  achievement  of  valproic  acid 
therapeutic  levels  may  increase  azacitidine
efficacy.
46 A  randomized  study  of  67  evaluable 
patients  with  MDS,  AML,  or  CMML  comparing 
decitabine  at  a  dose  of  20  mg/m
2 daily  for    5 
consecutive  days  every  28  days  with  or  without
valproic acid showed no significant difference.
47
Oral vorinostat (SAHA) at doses between 100 
and 300 mg 2 or 3-times daily for 14 days followed 
by 1-week rest has been used in 41 patients with 
relapsed  or  refractory  leukemias  or  MDS.  Seven 
patients  obtained  hematologic  improvement, 
including 2 CR and 2 CR with  incomplete blood 
count  recovery.
48 Preliminary  data  on  vorinostat 
combined with decitabine in AML patients showed 
only transient results in 30 patients with relapsed or 
refractory leukemia.
49
Oral MGCD0103 has shown promising activity 
alone  or  in  combination  with  azacitidine.  Further 
development  of  this  drug  is  uncertain  due  to 
significant  cardiac  side  effects,  including 
hemodynamically  significant  pericardial  effusion, 
observed in the follow-up of a randomized study of 
azacitidine with or  without MGCD0103.
43
Entinostat,  belinostat  and  romidepsin 
monotherapy have shown limited clinical activity in 
unselected AML/MDS patients in Phase I/II clinical 
trials.
43 Panobinostat  data  in  patients  with  MDS 
have not  yet  been  reported,  while  2  CR  were 
reported in 62 AML patients in a Phase I/II study 
using  oral  panobinostat  in  advanced  hematologic 
malignancies.
50
Other drugs: Clofarabine is a halogenated purine 
analogue  approved  by  FDA  for  the  treatment  of 
children  with  acute  lymphoblastic  leukemia  in 
relapse.  The  proposed  mechanism  of  action  of 
clofarabine  includes  not  just  incorporation  into 
DNA  with  induction  of  apoptosis,  but  also 
inhibition  of  ribonucleotide  reductase  and  DNA 
synthesis.
43 This drug has been explored in higher-
risk  MDS  and  AML.  The  MD  Anderson  group 
treated 32 MDS patients, 22 with  INT-2/high risk 
disease,  20  patients  with  prior  hypomethylating 
therapy failure, with three doses of clofarabine per 
os (40 mg/m
2, 30 mg/m
2 and 20 mg/m
2 daily for 5
days every 4 to 8 weeks). ORR was 43%, including 
25% CR, 9% HI and 9% clinical benefit. Response 
rates were lower in patients with a previous failure 
with  hypomethylating  agents.  Common  adverse 
events  were  gastrointestinal  and  hepatic 
disturbances and myelosuppression.
51
Ezatiostat  (TLK199,  TER199,  Telintra)  is  a 
glutathione  analog  exerting  biologic  effects  by 
indirect activation of Jun-N-terminal kinase (JNK).  
Ezatiostat’s  metabolite  TLK117  binds  to 
glutathione  S-transferase  P1-1  (GST  P1-1)  and 
causes its dissociation from JNK, activating JNK, 
with  consequent  induction  of  growth  and 
maturation of hematopoietic progenitors. Ezatiostat  
has been recently tested in a phase I study including 
45  lower-risk  MDS  patients.  No  dose-limiting 
toxicity was reached using 200 mg to 6000 mg daily 
per os for 7 days of a 21-day cycle, and common 
side  effects  were  gastrointestinal.  Seventeen 
patients (38%) achieved hematologic improvement 
using IWG criteria. Extended dosing schedules are 
being evaluated in a phase II study.
52
Tipifarnib  (R115777,  Zarnestra)  is  a 
farnesyltransferase  inhibitor  currently  in 
development  for  treatment  of  myeloid 
malignancies.  The  enzyme  farnesyltransferase  is 
important  for  membrane  attachment  of  the  Ras 
oncogene.  Constitutive  Ras  activation  and  Ras 
hyperactivity  contributes  to  cell  proliferation  and 
survival in a wide variety of neoplasms, including 
AML and MDS. Inhibition of farnesylation of other 
proteins  besides  Ras  may  account  for  tipifarnib  
activity in cells with wild-type Ras.
43 A number of
cell  lines  are  sensitive  to  farnesyltransferase 
inhibitors.  In  a  Phase  II  study  of  oral  tipifarnib, 
administered to 27 evaluable patients with MDS at 
a dose of 600 mg twice daily for 4 weeks, every 6-
weeks, three patients (11%) responded, including 2 
CR  and  1  PR.  Most  common  adverse  events 
included  myelosuppression,  rash,  fatigue,  and 
gastrointestinal  upset.
53 A  multicenter  Phase  II 
study  enrolled  82  patients  with  higher-risk  MDS, 
who received tipifarnib 300 mg orally twice daily 
for  21  days  of  each  28-day cycle.  Using  IWG 
criteria,  there  were  12  (15%)  CR,  and  14  (17%) 
hematologic improvements.
54
Conclusions:  New  agents  affecting  crucial 
pathogenetic  pathways  have  shown  to  induce 
significant  clinical  responses  in  MDS  and  have 
entered  clinical  practice,  changing  the  therapeutic Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
paradigm  and  guidelines.  Although  some  agents 
have been shown to increase survival, so far none 
can  be  considered  curative,  since  responses  are 
usually  time-limited  and  are  lost  following  drug 
discontinuation.  Further  developments  are
definitively required, including combination studies 
with different active drugs. The use of these new 
drugs  in  the  setting  of  allogenic  stem  cell 
transplantation  is  under  investigation  in  selected 
younger patients. A better understanding  of  MDS 
biology  will  warrant  more  targeted  therapy 
approaches in the future.
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